

## Correction of error Q3 (18) report

**Lund, Sweden, 08.00 CET, February 13, 2019** - BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, today announces that the report for the third quarter of 2018, published November 7, 2018, contained an error that arose in connection with the transition to a new reporting system. Due to the error, gross profit and the result for the third quarter of 2018 have been reported as SEK 1.3 million too high.

The error relates in its entirety to the segment EUROPE & REST OF WORLD. The error refers to internal profit calculation in inventories and was discovered when working on the fourth quarter report and has no impact on the company's previously communicated goals.

In the third quarter of 2018, gross profit was SEK 11.7 million (13.0), gross margin was 81.8% (91.0%) and net result was SEK -58.8 million (-57.5). Previously reported figures in parentheses.

For the first nine months of 2018, the gross profit was SEK 61.8 million (63.1), the gross margin was 84.0% (85.9%) and the net result was -130.8 (-129.5). Previously reported figures in parentheses.

**For more information, please contact:**

**BONESUPPORT AB**

Emil Billbäck, CEO  
+46 (0) 46 286 53 70

Håkan Johansson, CFO  
+46(0) 46 286 53 70  
ir@bonesupport.com

*This information is such information as BONESUPPORT HOLDING AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 CET on 13 February 2019.*

**About BONESUPPORT™**

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for its gentamicin eluting product is planned in 2020. The company is based in Lund, Sweden, and the net sales amounted to SEK 129 million in 2017. Please visit [www.bonesupport.com](http://www.bonesupport.com) for more information.

BONESUPPORT® and CERAMENT® are registered trademarks.